Ordinary Shares, $0.001 par value
- Symbol
- STE
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
STERIS plc
STENYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 11, 2026, STERIS plc (the “Company”) issued a press release announcing financial results for the three and twelve month periods ending March 31, 2026. A copy of this press release is attached hereto as Exhibit 99.1.…
Company context
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit www.steris.com.
Current securities
Recent company filings
- 10-Q filingNov 5, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementNov 4, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal ActivitiesNov 4, 2026
- Entry into a Material Definitive AgreementOct 13, 2026
- 4 filingOct 5, 2026
Registered securities in this filing
STERIS plc · 8-K · Filed 2026-05-11
2.700% Senior Notes due 2031
- Symbol
- STE/31
- Exchange
- NYSE
- Classification
- DEBT
3.750% Senior Notes due 2051
- Symbol
- STE/51
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On May 11, 2026, STERIS plc (the “Company”) issued a press release announcing financial results for the three and twelve month periods ending March 31, 2026. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Filed exhibits (1)
EX-99.1 2 ste03312026ex991.htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year • Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7% • Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share increased to $10.17 • Board approves new $1 billion share repurchase program DUBLIN, IRELAND - (May 11, 2026) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations grew 5% in the fourth quarter. Revenue from continuing operations for the full year fiscal 2026 increased 9% to $5.9 billion compared with $5.5 billion in fiscal 2025. Constant currency organic revenue growth from continuing operations grew 7% for fiscal 2026. “Fiscal 2026 was another rec…
Open exhibit ↗